RSV: Nirsevimab Provider Update and Increasing Uptake | January 25, 2024
Date of Presentation: January 25, 2024
Type: Past Presentation
Audience: Clinical
Program: Maternal and Child Health
Keywords: #children #nirsevimab #pediatrics #rsv #vaccination #vaccine
In this presentation, Paige Killelea MD, goes over a RSV: Nirsevimab Provider Update and Increasing Uptake. She covers RSV signs and symptoms, Disease burden, Current landscape of Nirsevimab & Dosing Guidelines, a quick note on Palivizumab, Abrysvo: RSV vaccination for Pregnant People, Provider talking points, Contraindications/precautions & Safety, as well as various FAQs.
Recording:
Presented by:
Dr. Paige Killelea, MD
Paige Killelea, MD is a pediatric resident at Seattle Children’s who is working with the DOH on projects related to Nirsevimab Implementation. She went to medical school at Baylor College of Medicine and is interested in public health, health equity and advocacy. She has experiences in global health and values the opportunity to learn from different communities. She plans to be a primary care pediatrician working to improve the health and well-being of children and their families.
Resources Provided:
- Compete the Evaluation/Claim Certificate of Completion
- Vaccine Adverse Event Reporting System
- Respiratory Syncytial Virus (RSV) Immunizations
- Healthcare Providers: RSV Prevention Information
- Frequently Asked Questions About RSV Immunization with Monoclonal Antibody for Children 19 Months and Younger
- RSV Immunization for Children 19 months and Younger
- ACIP and AAP Recommendations for Nirsevimab
- Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season
- Vaccines for Children (VFC) Operations Guide
- Native Boost
- VacciNative
Date added: January 25, 2024